Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04844749 · ClinicalTrials.gov registry record · Phase 3
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
A Phase 3 study, sponsored by Veru.
- Terminated
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT04844749 is a Phase 3 study that was terminated before completion, run by Veru. The registered enrollment target is 105 participants.
The verdict
NCT04844749, a Phase 3 study, was terminated before completion, sponsored by Veru.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.
Interventions
- DRUG VERU-111
- DRUG Enzalutamide, Abiraterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2023-05-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04844749
The ClinicalTrials.gov registry entry for NCT04844749 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VERU-111 is the first listed.
NCT04844749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04844749 about?
NCT04844749 is a clinical study titled "Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent". To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.
What is the current status of trial NCT04844749?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2021-06-24. Estimated completion is 2023-05-04.
What interventions are being tested in trial NCT04844749?
The interventions under investigation include: VERU-111 (DRUG), Enzalutamide, Abiraterone (DRUG).
Who is sponsoring clinical trial NCT04844749?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.